Carmat announces the completion of its capital increase with cancellation of the shareholders' pre-emptive subscription rights by way of a public offering, for a total gross amount of 16.5 million euros, including the partial exercise of the over-allotment option for 1.5 million.

The medical technology company plans to use these funds to strengthen its equity and finance its short-term working capital, and in particular to pursue the development of its production and sales, as well as its EFICAS clinical trial in France.

Following the offer, Carmat's 12-month financing requirement is around €50 million (with a financial horizon of end-February 2024), which could be reduced to €35 million (with a financial horizon of mid-May 2024) in the event of a definitive agreement with the EIB.

Copyright (c) 2024 CercleFinance.com. All rights reserved.